Nama's AI scorecard currently rates Lakefront Biotherapeutics Buy (7.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is LKFT's P/E ratio?

Lakefront Biotherapeutics trades at a trailing price-to-earnings ratio of 2.7.

When does LKFT report earnings?

Lakefront Biotherapeutics's next scheduled report is on Nov 11, 2026. Analysts expect EPS of $0.23.

What is the LKFT price target?

The median analyst price target from 3 analysts is $25.83, with a range of $21.17 – $43.82.

Is LKFT Shariah compliant?

Nama's AAOIFI-style screen reads Lakefront Biotherapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Lakefront Biotherapeutics (LKFT)

Healthcare · Biotechnology · NASDAQ

Lakefront Biotherapeutics (LKFT) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.20B, a trailing price-to-earnings ratio of 2.7 and a free-cash-flow yield of -13.8%. Over the most recent reported fiscal year, revenue grew 303.5%. Nama's AI scorecard rates it Buy, 7.0 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Buy · 7.0/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Lagging · -3.9% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-53.6%

How far the last close sits under the highest price of the past five years.

Market cap	$2.20B
Trailing P/E	2.7
Price / book	0.6
Price / sales	2.0
FCF yield	-13.8%
Dividend yield	—
Gross margin	97.5%
Operating margin	61.6%
Net margin	60.2%
Revenue growth (YoY)	+303.5%
Revenue growth (3-yr annual)	+66.4%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

LKFT earnings

Next report: Nov 11, 2026 (Q3 2026, EPS estimate $0.23). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 10, 2026	$0.03	-$11.50	+100.3%	$13.59M
Q1 2026	May 6, 2026	$0.21	-$0.97	+121.7%	$7.27M
Q4 2025	Mar 26, 2026	$12.27	-$0.07	+17628.6%	$1.01B
Q3 2025	Nov 5, 2025	-$0.18	-$0.28	+35.7%	$79.84M

LKFT analyst price target

Median target $25.83 from 3 analysts, ranging $21.17 – $43.82.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live LKFT data on Nama Insights →

LKFT FAQ

Is LKFT a buy?: Nama's AI scorecard currently rates Lakefront Biotherapeutics Buy (7.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is LKFT's P/E ratio?: Lakefront Biotherapeutics trades at a trailing price-to-earnings ratio of 2.7.
When does LKFT report earnings?: Lakefront Biotherapeutics's next scheduled report is on Nov 11, 2026. Analysts expect EPS of $0.23.
What is the LKFT price target?: The median analyst price target from 3 analysts is $25.83, with a range of $21.17 – $43.82.
Is LKFT Shariah compliant?: Nama's AAOIFI-style screen reads Lakefront Biotherapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.